Eton Pharmaceuticals (ETON) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $17.3M, up 117% year-over-year, driven by strong product sales, new launches, and acquisitions of INCRELEX® and GALZIN®.

• Achieved 17 consecutive quarters of sequential product revenue growth, with significant contributions from Alkindi Sprinkle and Increlex.

• Out-licensed INCRELEX® international rights, recognized $1.8M in licensing revenue and $2.5M in deferred revenue, and received $4.3M upfront.

• Net loss widened to $1.6M ($0.06/share) due to higher R&D and G&A expenses, despite non-GAAP net income of $2.4M ($0.07/share).

• Advanced late-stage pipeline with NDA for ET-600 submitted and ET-400 launch readiness for Q2/Q3 2025.

Financial highlights

• Net revenue was $17.3M in Q1 2025, up from $8.0M in Q1 2024; product sales reached $14.0M, a 76% increase.

• Licensing revenue totaled $3.3M, including $1.8M from INCRELEX® out-licensing and $1.5M from DS-200 milestone.

• Adjusted gross profit was $12.0M (69.5% margin), up from $5.2M (65.6%) year-over-year; gross profit was $9.9M.

• Adjusted EBITDA was $3.7M, up from $0.5M; adjusted EBITDA margin improved to 21% from 6% year-over-year.

• Cash and equivalents stood at $17.4M at quarter end, with $2.1M operating cash flow generated.

Outlook and guidance

• Expects sequential quarter-over-quarter product sales growth through 2025, targeting ~$80M annual revenue run rate by year-end.

• Full-year 2025 adjusted gross margin expected at ~70%, with long-term margin exceeding 75% by 2028.

• ET-400 launch anticipated in Q2/Q3 2025, with ET-600 potential approval and launch in Q1 2026.

• Management expects existing cash and product revenues to fund operations for at least the next 12 months.

• No further significant SG&A investments planned for 2025; adjusted G&A spending to remain flat or slightly decline.